Damali N Martin1, Adrienne M Starks, Stefan Ambs. 1. Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4258, USA.
Abstract
PURPOSE OF REVIEW: Prostate cancer mortality rates are highest among men of African ancestry in the United States and globally. Environmental exposures and ancestry-related factors may influence tumor biology and induce a more aggressive disease in this population. Here, we summarize the most recent advances in our understanding of race/ethnic differences in the tumor biology of prostate cancer with an emphasis on the excess disease burden among African-Americans. RECENT FINDINGS: Results from several DNA methylation studies showed an increased prevalence in DNA hypermethylation at disease-related loci in tumors from African-American patients compared with tumors from European-American patients. Analyses of genome-wide gene expression in prostate tumors revealed frequent alterations in the expression of genes related to immunobiology among the African-American patients, consistent with immune response differences between them and their European-American counterparts. Lastly, population differences in the frequency of oncogenic erythroblast transformation-specific family of transcription factors (ETS)-related gene rearrangements were evaluated in three studies that showed that these alterations manifest themselves most commonly in tumors from men of European ancestry, but are significantly less frequent in men of African ancestry, whereas least common in men of Asian ancestry. SUMMARY: Analysis of tumor markers indicates that tumor biological differences may exist between prostate cancer patients of African ancestry and those of European or Asian ancestry. These differences could affect disease aggressiveness and response to therapy.
PURPOSE OF REVIEW: Prostate cancer mortality rates are highest among men of African ancestry in the United States and globally. Environmental exposures and ancestry-related factors may influence tumor biology and induce a more aggressive disease in this population. Here, we summarize the most recent advances in our understanding of race/ethnic differences in the tumor biology of prostate cancer with an emphasis on the excess disease burden among African-Americans. RECENT FINDINGS: Results from several DNA methylation studies showed an increased prevalence in DNA hypermethylation at disease-related loci in tumors from African-American patients compared with tumors from European-American patients. Analyses of genome-wide gene expression in prostate tumors revealed frequent alterations in the expression of genes related to immunobiology among the African-American patients, consistent with immune response differences between them and their European-American counterparts. Lastly, population differences in the frequency of oncogenic erythroblast transformation-specific family of transcription factors (ETS)-related gene rearrangements were evaluated in three studies that showed that these alterations manifest themselves most commonly in tumors from men of European ancestry, but are significantly less frequent in men of African ancestry, whereas least common in men of Asian ancestry. SUMMARY: Analysis of tumor markers indicates that tumor biological differences may exist between prostate cancerpatients of African ancestry and those of European or Asian ancestry. These differences could affect disease aggressiveness and response to therapy.
Authors: Matthew L Freedman; Christopher A Haiman; Nick Patterson; Gavin J McDonald; Arti Tandon; Alicja Waliszewska; Kathryn Penney; Robert G Steen; Kristin Ardlie; Esther M John; Ingrid Oakley-Girvan; Alice S Whittemore; Kathleen A Cooney; Sue A Ingles; David Altshuler; Brian E Henderson; David Reich Journal: Proc Natl Acad Sci U S A Date: 2006-08-31 Impact factor: 11.205
Authors: V Srikantan; Z Zou; G Petrovics; L Xu; M Augustus; L Davis; J R Livezey; T Connell; I A Sesterhenn; K Yoshino; G S Buzard; F K Mostofi; D G McLeod; J W Moul; S Srivastava Journal: Proc Natl Acad Sci U S A Date: 2000-10-24 Impact factor: 11.205
Authors: Yien Che Tsai; Arnulfo Mendoza; Jennifer M Mariano; Ming Zhou; Zlatka Kostova; Bo Chen; Timothy Veenstra; Stephen M Hewitt; Lee J Helman; Chand Khanna; Allan M Weissman Journal: Nat Med Date: 2007-11-25 Impact factor: 53.440
Authors: Nikolai N Khodarev; Paul Roach; Sean P Pitroda; Daniel W Golden; Mihir Bhayani; Michael Y Shao; Thomas E Darga; Mara G Beveridge; Ravi F Sood; Harold G Sutton; Michael A Beckett; Helena J Mauceri; Mitchell C Posner; Ralph R Weichselbaum Journal: PLoS One Date: 2009-06-08 Impact factor: 3.240
Authors: Wei Zhang; Bin Yi; Chao Wang; Dongquan Chen; Sejong Bae; Shi Wei; Rong-Jun Guo; Changming Lu; Lisa L H Nguyen; Wei-Hsiung Yang; James W Lillard; Xingyi Zhang; Lizhong Wang; Runhua Liu Journal: Clin Cancer Res Date: 2015-12-28 Impact factor: 12.531
Authors: Tiffany A Wallace; Ronan F Downey; Caleb J Seufert; Aaron Schetter; Tiffany H Dorsey; Carol A Johnson; Radoslav Goldman; Christopher A Loffredo; Peisha Yan; Francis J Sullivan; Francis J Giles; Feng Wang-Johanning; Stefan Ambs; Sharon A Glynn Journal: Carcinogenesis Date: 2014-05-23 Impact factor: 4.944
Authors: Wei Liu; Yue Zhang; Shi Wei; Sejong Bae; Wei-Hsiung Yang; Gary J Smith; James L Mohler; Elizabeth T H Fontham; Jeannette T Bensen; Guru P Sonpavde; Guo-Yun Chen; Runhua Liu; Lizhong Wang Journal: Prostate Date: 2020-03-13 Impact factor: 4.104
Authors: Ryan C Widau; Akash D Parekh; Mark C Ranck; Daniel W Golden; Kiran A Kumar; Ravi F Sood; Sean P Pitroda; Zhengkai Liao; Xiaona Huang; Thomas E Darga; David Xu; Lei Huang; Jorge Andrade; Bernard Roizman; Ralph R Weichselbaum; Nikolai N Khodarev Journal: Proc Natl Acad Sci U S A Date: 2014-01-13 Impact factor: 11.205